Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cognition Therapeutics Inc
(NQ:
CGTX
)
1.950
+0.020 (+1.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
55,056
Open
1.930
Bid (Size)
1.760 (50)
Ask (Size)
1.950 (8)
Prev. Close
1.930
Today's Range
1.870 - 1.970
52wk Range
0.9001 - 3.490
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Monday's After-Market Session
April 22, 2024
Via
Benzinga
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
April 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+0.52%
+0.52%
1 Month
+7.14%
+7.14%
3 Month
-18.75%
-18.75%
6 Month
+71.05%
+71.05%
1 Year
+14.04%
+14.04%
More News
Read More
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
April 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
A Preview Of Cognition Therapeutics's Earnings
March 25, 2024
Via
Benzinga
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
April 01, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023
March 26, 2024
Via
InvestorPlace
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
March 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering
March 15, 2024
Via
Investor Brand Network
Earnings Scheduled For March 26, 2024
March 26, 2024
Via
Benzinga
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
March 15, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
March 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
March 14, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
March 11, 2024
Via
Benzinga
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
March 11, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
March 06, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
February 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
February 06, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 04, 2024
Via
Benzinga
Cognition Therapeutics CEO Issues Letter to Shareholders
January 04, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
December 11, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 04, 2023
Via
Benzinga
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
November 16, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
November 15, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
November 07, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.